12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Iclusig ponatinib: Phase II data

Interim data from 20 treatment-naïve patients with Ph+ ALL in an open-label, U.S. Phase II trial showed that once-daily 45 mg oral Iclusig plus hyperCVAD chemotherapy led to a 1-year progression-free survival (PFS) rate of 100% and 1-year overall survival (OS) rate of 95%. Additionally, all patients were in complete remission after 1 cycle. Of the 17 patients known...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >